NASDAQ:MDNA - Medicenna Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $10.00
  • Forecasted Upside: 498.80 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$1.67
▲ +0.1 (6.37%)

This chart shows the closing price for MDNA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Medicenna Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MDNA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MDNA

Analyst Price Target is $10.00
▲ +498.80% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Medicenna Therapeutics in the last 3 months. The average price target is $10.00, with a high forecast of $12.00 and a low forecast of $7.00. The average price target represents a 498.80% upside from the last price of $1.67.

This chart shows the closing price for MDNA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 investment analysts is to buy stock in Medicenna Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/15/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/13/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/12/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/12/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/10/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/8/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/7/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/7/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/15/2021HC WainwrightReiterated RatingBuy$7.00Low
9/22/2021Bloom BurtonInitiated CoverageBuy$11.00Medium
6/1/2021HC WainwrightLower Price TargetBuy$8.00 ➝ $7.00High
12/17/2020OppenheimerInitiated CoverageOutperform$12.00High
9/10/2020HC WainwrightInitiated CoverageBuy$8.00Low
8/24/2020Brookline Capital ManagementReiterated RatingBuyMedium
8/24/2020Bloom BurtonReiterated RatingBuyMedium
(Data available from 12/7/2016 forward)

News Sentiment Rating

0.39 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/11/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/10/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/10/2021
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/9/2021
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/8/2021
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
10/8/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/7/2021
  • 1 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/7/2021

Current Sentiment

  • 1 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
Medicenna Therapeutics logo
Medicenna Therapeutics Corp. is a clinical stage immuno-oncology company. It engages in development and commercialization of selective versions of IL-2, IL-4 and IL-13 Superkines and Empowered Cytokines for the treatment of cancers. The company was founded by Fahar Merchant and Rosemina Merchant on February 2, 2015 and is headquartered in Toronto, Canada.
Read More

Today's Range

Now: $1.67
Low: $1.51
High: $1.72

50 Day Range

MA: $2.24
Low: $1.57
High: $2.85

52 Week Range

Now: $1.67
Low: $1.51
High: $6.84

Volume

57,084 shs

Average Volume

165,121 shs

Market Capitalization

$89.92 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.98

Frequently Asked Questions

What sell-side analysts currently cover shares of Medicenna Therapeutics?

The following sell-side analysts have issued research reports on Medicenna Therapeutics in the last twelve months: Bloom Burton, HC Wainwright, and Oppenheimer Holdings Inc..
View the latest analyst ratings for MDNA.

What is the current price target for Medicenna Therapeutics?

3 Wall Street analysts have set twelve-month price targets for Medicenna Therapeutics in the last year. Their average twelve-month price target is $10.00, suggesting a possible upside of 536.9%. Oppenheimer Holdings Inc. has the highest price target set, predicting MDNA will reach $12.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $7.00 for Medicenna Therapeutics in the next year.
View the latest price targets for MDNA.

What is the current consensus analyst rating for Medicenna Therapeutics?

Medicenna Therapeutics currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MDNA will outperform the market and that investors should add to their positions of Medicenna Therapeutics.
View the latest ratings for MDNA.

What other companies compete with Medicenna Therapeutics?

How do I contact Medicenna Therapeutics' investor relations team?

Medicenna Therapeutics' physical mailing address is 200-1920 Yonge Street, Toronto A6, M4S 3E2. The company's listed phone number is (416) 648-5555 and its investor relations email address is [email protected] The official website for Medicenna Therapeutics is www.medicenna.com.